Leukemia Lawyer Assistance for Financial Recovery Nationwide

Leukemia settlements
Leukemia Attorneys - Recovering Compensation Nationwide
FOR MORE INFORMATION
Please call 1-800-923-6376.
We will gladly answer your questions and send a
FREE booklet regarding:

Financial & Legal Assistance
  • Hiring a Lawyer
  • Recovery Process
  • Attorney Agreement
  • Settlement vs. Trial
  • All Info on Website
Patient Information
  • New treatment options
  • New medications
  • Doctor locations
  • Clinical Trials

Leukemia Cancer News - Return to Menu

Arsenic Trioxide and Pixantrone Highlighted in 42 Abstracts and Presentations at The American Society of Hematology Meeting

Updates on two phase II pixantrone studies demonstrate high rates of complete responses


SEATTLE, Nov. 23 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; Nuovo Mercato) announced today that clinical investigators from cancer research centers will report data from recent and ongoing clinical trials of arsenic trioxide (TRISENOX®) and pixantrone in a broad range of hematologic cancers at the 46th Meeting of the American Society of Hematology (ASH) from December 4-7 in San Diego, Calif. Data on arsenic trioxide will be presented in the treatment of leukemia, multiple myeloma and myelodysplasia. Two phase II studies will provide updated information on the potential clinical activity of pixantrone in non-Hodgkin's lymphoma.

The following are some of the clinical research abstracts on arsenic trioxide and pixantrone that will be presented in oral or poster sessions. For a complete list of arsenic trioxide and pixantrone presentations and abstracts at ASH, please refer to the CTI website at http://www.cticseattle.com/investors_news-updates.htm . To access a complete list of abstracts at ASH, refer to the conference website at http://www.hematology.org/meeting/abstracts.cfm.

Saturday, December 4, 2004, at 6:00 pm PT
Preliminary Results of a Phase I/II Trial of BBR-2778 (Pixantrone) in Combination with Fludarabine, Dexamethasone, and Rituximab (FPD-R) in the Treatment of Patients with Relapsed/Refractory Indolent Non-Hodgkin's
Lymphoma (NHL)-Poster Session
Dr. Luis Fayad, MD Anderson Cancer Center, Houston, TX

Saturday, December 4, 2004, at 6:00 pm PT
TRISENOX(R) (arsenic trioxide) in Patients with Myelodysplastic Syndromes (MDS): Preliminary Results of a Phase I/II Study-Poster Session
Dr. Norbert Vey, Institut Paoli-Calmettes, Marseille, France

Sunday, December 5, 2004, at 6:00 pm PT
Preliminary Phase II Study Results of BBR2778 in Combination with Cyclophosphamide, Vincristine, and Prednisone in Patients with Relapsed Aggressive Non-Hodgkins Lymphoma-Poster Session
Dr. Raoul Herbrecht, Hopital de Hautepierre, Strasbourg, France

Sunday, December 5, 2004, at 6:00 pm PT
A Phase I/II Multicenter, Safety and Efficacy Study of Combination Treatment with Melphalan, Arsenic Trioxide and Vitamin C (MAC) in Patients with Relapsed or Refractory Multiple Myeloma-Poster Session
Dr. James Berenson, Institute for Myeloma and Bone Marrow Cancer

Sunday, December 5, 2004, at 6:00 pm PT
Arsenic Trioxide (TRISENOX(R) ATO), Ascorbic Acid (AA) and Dexamethasone (Dex) Pulses (TAD) for Relapsed Refractory Progressive Multiple Myeloma (MM) Patients (pts); a Final Report-Poster Session
Dr. Mohamad Hussein, Cleveland Clinic Foundation, Taussig Cancer Center

Monday, December, 6, 2004 at 1:30 pm PT
Use of All-Transretinoic Acid (ATRA) + Arsenic Trioxide (ATO) To Eliminate or Minimize Use of Chemotherapy (CT) in Untreatable Acute Promyelocytic Leukemia (APL)-Oral Session
Dr. Elihu Estey, The University of Texas, M. D. Anderson Cancer Center

About Cell Therapeutics, Inc.

Based in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.cticseattle.com.

-----------------------------------------
Source: Cell Therapeutics, Inc.

 
FREE INFO PACKET REQUEST FORM
Please send me:
 
Financial & Legal Assistance Booklet:
No     Yes
Leukemia Patient Support Booklet:
No     Yes
 
First Name:
 
Last Name:
 
Address Line 1:
 
Address Line 2:
 
City:
 
State:
 
Zip Code:
 
Telephone:
 
Email:
 
   
Have you or a loved one, been diagnosed with or have:
Acute Myelogenous
Leukemia (AML)?

  No   Yes
Myelodysplastic Syndrome (MDS)?

  No   Yes
Aplastic Anemia?

  No   Yes
Non-Hodgkin Lymphoma (NHL)?

  No   Yes
Any other Leukemia or
Blood Disease?
( In the comments please
state the diagnosis)

  No   Yes
Did you or your loved one ever
work around benzene?
At Risk Jobs / Exposure

  No   Yes
How old is the patient?
(Should be 30 or older.)
  
 
Comment / Specific Request:
 
 
Or call 1-800-923-6376 to receive your information packet.